Phase 3
N=326
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
Pulmonary Hypertension · Interstitial Lung Disease · Combined Pulmonary Fibrosis and Emphysema
Bottom Line
View on ClinicalTrials.gov: NCT02630316 ↗Enrolled (actual)
326
Serious AEs
24.5%
Results posted
Jul 2021
Primary outcome: Primary: Change in 6-minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 16 — -9.0; 6.0 meters — p=0.0043
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Inhaled Treprostinil (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- United Therapeutics
- Primary completion
- Dec 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in 6-minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 16 |
-9.0; 6.0 | 0.0043 sig |
| SECONDARY Change in Plasma Concentration of N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) From Baseline to Week 16 |
20.65; -22.65 | <0.0001 sig |
| SECONDARY Incidence of Clinical Worsening |
54; 37 | 0.0410 sig |
| SECONDARY Change in Peak 6-minute Walk Distance (6MWD) From Baseline to Week 12 |
-3.0; 8.0 | 0.0041 sig |
| SECONDARY Change in Trough 6-minute Walk Distance (6MWD) From Baseline to Week 15 |
-9.0; 0.0 | 0.0432 sig |
Summary
This was a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study included 326 patients at approximately 120 clinical trial centers. The treatment phase of the study lasted approximately 16 weeks. Patients who completed all required assessments were eligible to enter an open-label, extension study (RIN-PH-202).
Eligibility Criteria
Inclusion Criteria
- Subject voluntarily gave informed consent to participate in the study.
- Males and females aged 18 years or older at the time of informed consent.
a. Females of reproductive potential were non-pregnant (as confirmed by a urine pregnancy test at screening) and non-lactating, and: i. Abstained from intercourse (when in line with their preferred and usual lifestyle), or ii. Used 2 medically acceptable, highly effective forms of contraception for the duration of study, and at least 30 days after discontinuing study drug.
b. Males with a partner of childbearing potential used condoms for the duration of treatment and for at least 48 hours after discontinuing study drug.
- The subject had a confirmed diagnosis of WHO Group 3 PH based on computed tomography (CT) imaging which was performed within 6 months prior to randomization and demonstrated evidence of diffuse parenchymal lung disease. Subjects had any form of ILD or CPFE.
- Subjects were required to have a right heart catheterization (RHC) within 1 year prior to randomization with the following documented parameters:
- Pulmonary vascular resistance (PVR) >3 Wood Units (WU) and
- A pulmonary capillary wedge pressure (PCWP) of 25 mmHg
- Baseline 6MWD ≥100 m.
- Subjects on a chronic medication for underlying lung disease (ie, pirfenidone, nintedanib, etc) were on a stable and optimized dose for ≥30 days prior to randomization.
- In the opinion of the Investigator, the subject was able to communicate effectively with study personnel, and was considered reliable, willing and likely to be cooperative with protocol requirements, including attending all study visits.
- Subjects with connective tissue disease (CTD) had a Baseline forced vital capacity (FVC) of 15 mmHg
- Left ventricular ejection fraction 10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
- Current use of any inhaled tobacco/marijuana products or significant history of drug abuse at the time of informed consent.
- Exacerbation of underlying lung disease or active pulmonary or upper respiratory infection within 30 days of randomization.
- Initiation of pulmonary rehabilitation within 12 weeks prior to randomization.
- In the opinion of the Investigator, the subject had any condition that would interfere with the interpretation of study assessments or has any disease or condition (ie, peripheral vascular disease, musculoskeletal disorder, morbid obesity) that would likely be the primary limit to ambulation (as opposed to PH).
- Use of any investigational drug/device, or participation in any investigational study with therapeutic intent within 30 days prior to randomization.
- Severe concomitant illness limiting life expectancy (<6 months).
- Acute pulmonary embolism within 90 days of randomization.
Data sourced from ClinicalTrials.gov (NCT02630316). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.